InstalabLoading...
InstalabLoading...
Your fat cells are supposed to hold onto stored fat until your body actually needs the energy. When that storage system starts leaking, individual fatty acids spill into your bloodstream in amounts your body cannot easily use, and they begin to interfere with how your muscles, liver, and blood vessels respond to insulin. This test offers a window into that leaky-storage problem before it shows up as high blood sugar.
This is a research-grade measurement. It is not part of a standard lipid panel, and major guidelines do not recommend it for routine screening. That said, for someone tracking their metabolic health closely, NEFA (non-esterified fatty acids, also called free fatty acids) can add an early-warning layer that standard tests miss. Treat it as an exploratory data point, not a diagnosis.
NEFA are fatty acid molecules that have been released from stored body fat and travel in your blood attached to albumin, the most common protein in your blood. Over 99% of circulating NEFA is bound to albumin. Your fat tissue is the main source: stored triglycerides are broken down and the individual fatty acids are released into circulation to be used as fuel by your heart, skeletal muscle, and other tissues.
Insulin is the main brake on this process. After a meal, insulin tells fat cells to hold onto their stores, and NEFA levels drop sharply. Between meals and during sleep, insulin falls and NEFA rises to supply energy. In insulin resistance, that brake stops working properly, and NEFA stays inappropriately high even when it should be suppressed.
Elevated NEFA is one of the earliest footprints of a specific kind of insulin resistance: your fat tissue failing to respond to insulin's signal to stop releasing fat. This matters because fat-tissue insulin resistance often shows up before muscle or liver insulin resistance, and before fasting glucose starts to drift upward.
In the Atherosclerosis Risk in Communities (ARIC) study, people in the highest quartile of fasting NEFA had about 1.6 times the risk of developing type 2 diabetes compared to the lowest quartile, even after adjusting for BMI, fasting glucose, insulin, and triglycerides (hazard ratio 1.63, 95% CI 1.04-2.57). A case-control study in newly diagnosed diabetes found plasma free fatty acid levels nearly three times higher than in healthy controls, with a reported sensitivity of 92% and specificity of 90% for distinguishing the two groups. These numbers come from research cohorts, not from a validated clinical cutpoint.
When fat cells leak fatty acids, a lot of them end up at the liver. The liver repackages them into triglycerides, and when supply outpaces export, fat accumulates inside liver cells. This is a core mechanism in non-alcoholic fatty liver disease (NAFLD). A cross-sectional study found that people with NAFLD had significantly higher serum NEFA than controls, and elevated NEFA independently predicted advanced liver fibrosis (scarring) in that population.
NEFA has been linked to worse outcomes most consistently in older adults and in people who already have cardiovascular disease. In the Cardiovascular Health Study, a cohort of 4,707 older adults followed for a median of 11.8 years, each standard-deviation increase in plasma free fatty acids was associated with about a 14% higher risk of death from any cause (HR 1.14, 95% CI 1.09-1.18) after full adjustment. A later analysis from the same study found a similar pattern (adjusted HR 1.17 per SD, 95% CI 1.10-1.23).
In the Ludwigshafen Risk and Cardiovascular Health (LURIC) study of 3,315 people undergoing coronary angiography, those in the highest NEFA quartile had about 1.58 times the risk of death from any cause and about 1.83 times the risk of cardiovascular death compared to the lowest quartile, independent of standard cardiovascular risk factors. A study in 623 elderly men with chronic kidney disease found that each doubling of NEFA was associated with about a 51% higher risk of cardiovascular death (HR 1.51, 95% CI 1.15-1.99).
The picture is more mixed in healthier populations. The Multi-Ethnic Study of Atherosclerosis (MESA), which enrolled 6,678 generally healthy adults, found that fasting NEFA was not associated with new coronary heart disease or cardiovascular disease events after full adjustment, and showed only a borderline link with all-cause mortality (HR 1.07 per SD, 95% CI 1.00-1.14). Associations with heart failure have been similarly inconsistent across cohorts. In practical terms: elevated NEFA is more likely to matter for your mortality risk if you already have cardiovascular disease or kidney disease than if you are healthy.
There are no guideline-endorsed clinical cutpoints for NEFA. The ranges below come from published research studies and should be treated as orientation, not as diagnostic thresholds. Before looking at the numbers, know that NEFA is highly sensitive to fasting status, stress, and time of day, which is the single biggest reason numbers vary.
| Tier | Range (mmol/L) | What It Suggests |
|---|---|---|
| Research-reported healthy adult range | 0.2 to 0.8 | Typical interval reported in method-validation and healthy-population studies |
| Typical fasting level in healthy adults (OMNI Heart) | About 0.14 mEq/L (roughly 0.4 to 0.5 mmol/L) | Average seen across three healthful dietary patterns in a controlled trial |
| Research-proposed cutpoint for type 2 diabetes | Above 0.92 mmol/L (919 micromolar) | Case-control analysis reported about 84% accuracy for distinguishing diabetes from controls |
Sources: OMNI Heart crossover trial (Ahiawodzi et al., 2023); Brunk and Swanson (1981) assay validation; Shiri et al. (2024) type 2 diabetes case-control study.
These tiers are drawn from published research. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend.
Women tend to have higher NEFA than men, and saturated fatty acid concentrations rise with age in women but not in men. There is no established sex- or age-specific clinical cutpoint, and ethnic variation appears limited.
NEFA has unusually high biological variability. In a study of healthy adults measured on 12 consecutive days, the within-person coefficient of variation was about 45%, meaning your own level can swing by almost half from one day to the next without anything being wrong. That is far higher than most blood tests people are used to.
A single reading is not enough to know where you stand. If you are going to track NEFA, standardize the conditions: same lab, same fasting window (a true overnight fast of at least 10 to 12 hours), same time of day, and no intense exercise in the preceding 24 hours. Get a baseline, repeat it once within a couple of weeks to confirm your starting point, then retest every 3 to 6 months if you are actively changing your diet, activity, or medications. Annual checks are a reasonable minimum for someone tracking metabolic health over the long term.
There is also evidence that NEFA may not predict your future metabolic trajectory as well as it reflects your current metabolic state. A longitudinal study found strong cross-sectional associations between NEFA and metabolic syndrome features, but no predictive relationship between baseline NEFA and the development of glucose intolerance 4.5 years later. That argues for using NEFA as a current-state snapshot alongside other markers, not as a standalone future-risk predictor.
Because NEFA swings so quickly with hormonal state, several everyday conditions can distort a reading and lead you the wrong direction.
Some medications also lower NEFA without changing your underlying metabolic health. Statins reduce plasma NEFA by roughly 19 to 21%. Niacin and acipimox can drop NEFA by 20 to 50% by suppressing fat-tissue lipolysis. Fibrates and omega-3 fatty acids also lower NEFA. If you are on any of these drugs, your NEFA number reflects the drug's effect, and comparing against pre-treatment levels is the only meaningful way to interpret it.
Evidence-backed interventions that affect your NEFA level
Non-Esterified Fatty Acids is best interpreted alongside these tests.